Lord Abbett & CO. LLC Buys 188,685 Shares of Evolus, Inc. (NASDAQ:EOLS)

Lord Abbett & CO. LLC raised its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 23.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 995,449 shares of the company’s stock after purchasing an additional 188,685 shares during the period. Lord Abbett & CO. LLC owned 1.57% of Evolus worth $16,126,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC grew its holdings in Evolus by 268.0% during the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after buying an additional 68,213 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Evolus by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company’s stock valued at $19,616,000 after acquiring an additional 11,027 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Evolus by 47.0% in the third quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after purchasing an additional 29,396 shares in the last quarter. Wellington Management Group LLP increased its position in Evolus by 30.3% in the third quarter. Wellington Management Group LLP now owns 175,039 shares of the company’s stock worth $2,836,000 after purchasing an additional 40,715 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Evolus during the third quarter valued at $132,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Barclays increased their price target on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research note on Monday, September 16th.

Evolus Price Performance

EOLS opened at $11.51 on Monday. The business has a fifty day moving average of $14.48 and a 200 day moving average of $13.85. The stock has a market cap of $728.81 million, a P/E ratio of -12.65 and a beta of 1.27. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 52-week low of $9.65 and a 52-week high of $17.82.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.